메뉴 건너뛰기




Volumn 10, Issue 5, 2004, Pages 394-403

The World Health Organization classification of myeloproliferative and myelodysplastic syndromes

Author keywords

Myelodysplastic syndromes; Myeloproliferative disorders; WHO classification

Indexed keywords

RETICULIN;

EID: 3343009049     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdip.2004.04.002     Document Type: Conference Paper
Times cited : (4)

References (18)
  • 5
    • 0019952276 scopus 로고
    • Proposals for the classification of the myelodysplastic syndromes
    • Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 51:1982;189-199
    • (1982) Br J Haematol , vol.51 , pp. 189-199
    • Bennett, J.M.1    Catovsky, D.2    Daniel, M.T.3
  • 6
    • 0028069002 scopus 로고
    • The chronic myeloid leukaemias: Guidelines for distinguishing granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals from the French-American-British Cooperative Leukaemia group
    • Bennett J.M., Catovsky D., Daniel M.T., et al. The chronic myeloid leukaemias. guidelines for distinguishing granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals from the French-American-British Cooperative Leukaemia group Br J Haematol. 87:1994;746-754
    • (1994) Br J Haematol , vol.87 , pp. 746-754
    • Bennett, J.M.1    Catovsky, D.2    Daniel, M.T.3
  • 7
    • 0032857774 scopus 로고    scopus 로고
    • The relationship between the myeloproliferative syndromes and the myeloproliferative disorders
    • Bain B.J. The relationship between the myeloproliferative syndromes and the myeloproliferative disorders. Leukaemia Lymphoma. 34:1999;443-449
    • (1999) Leukaemia Lymphoma , vol.34 , pp. 443-449
    • Bain, B.J.1
  • 8
    • 0032823415 scopus 로고    scopus 로고
    • Thrombocytosis and sideroblastic erythropoiesis: A mixed myeloproliferative myelodysplastic syndrome
    • Gupta R., Abdalla S.H., Bain B.J. Thrombocytosis and sideroblastic erythropoiesis. a mixed myeloproliferative myelodysplastic syndrome Leukaemia Lymphoma. 34:1999;615-619
    • (1999) Leukaemia Lymphoma , vol.34 , pp. 615-619
    • Gupta, R.1    Abdalla, S.H.2    Bain, B.J.3
  • 9
    • 0344987881 scopus 로고    scopus 로고
    • A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
    • Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 348:2003;1201-1214
    • (2003) N Engl J Med , vol.348 , pp. 1201-1214
    • Cools, J.1    Deangelo, D.J.2    Gotlib, J.3
  • 10
    • 2942545086 scopus 로고    scopus 로고
    • The idiopathic hypereosinophilic syndrome and eosinophilic leukaemias
    • Bain B.J. The idiopathic hypereosinophilic syndrome and eosinophilic leukaemias. Haematologica. 89:2004;134-138
    • (2004) Haematologica , vol.89 , pp. 134-138
    • Bain, B.J.1
  • 11
    • 0038487039 scopus 로고    scopus 로고
    • Cytogenetic and molecular genetic aspects of eosinophilic leukaemia
    • Bain B.J. Cytogenetic and molecular genetic aspects of eosinophilic leukaemia. Br J Haematol. 122:2003;173-179
    • (2003) Br J Haematol , vol.122 , pp. 173-179
    • Bain, B.J.1
  • 12
    • 0942276859 scopus 로고    scopus 로고
    • Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment with the myeloproliferative variant of hypereosinophilic syndrome
    • in press.
    • Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment with the myeloproliferative variant of hypereosinophilic syndrome. Blood, 2004, in press.
    • (2004) Blood
    • Klion, A.D.1    Robyn, J.2    Akin, C.3
  • 13
    • 10744228486 scopus 로고    scopus 로고
    • CHIC2 deletion, a surrogate marker for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
    • Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate marker for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 102:2003;3093-3098
    • (2003) Blood , vol.102 , pp. 3093-3098
    • Pardanani, A.1    Ketterling, R.P.2    Brockman, S.R.3
  • 14
    • 0017162163 scopus 로고
    • Proposals for the classification of the acute leukaemias (FAB cooperative group)
    • Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias (FAB cooperative group). Br J Haematol. 33:1976;451-458
    • (1976) Br J Haematol , vol.33 , pp. 451-458
    • Bennett, J.M.1    Catovsky, D.2    Daniel, M.T.3
  • 15
    • 0033757263 scopus 로고    scopus 로고
    • Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients
    • Germing U., Gatterman N., Strupp C., et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes. a retrospective analysis of 1600 patients Leuk Res. 24:2001;983-992
    • (2001) Leuk Res , vol.24 , pp. 983-992
    • Germing, U.1    Gatterman, N.2    Strupp, C.3
  • 16
    • 0036202064 scopus 로고    scopus 로고
    • The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1
    • Macdonald D., Reiter A., Cross N.C.P. The 8p11 myeloproliferative syndrome. a distinct clinical entity caused by constitutive activation of FGFR1 Acta Haematol. 107:2002;101-107
    • (2002) Acta Haematol , vol.107 , pp. 101-107
    • MacDonald, D.1    Reiter, A.2    Cross, N.C.P.3
  • 17
    • 0036202529 scopus 로고    scopus 로고
    • Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor beta
    • Steer E.J., Cross N.C.P. Myeloproliferative disorders with translocations of chromosome 5q31-35. role of the platelet-derived growth factor receptor beta Acta Haematol. 107:2002;113-122
    • (2002) Acta Haematol , vol.107 , pp. 113-122
    • Steer, E.J.1    Cross, N.C.P.2
  • 18
    • 0037103624 scopus 로고    scopus 로고
    • Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    • Apperley J., Gardembas M., Melo J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 347:2002;481-487
    • (2002) N Engl J Med , vol.347 , pp. 481-487
    • Apperley, J.1    Gardembas, M.2    Melo, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.